Skip to main content

GUIDED THERAPEUTICS INC

corporate_fare Company Profile

GUIDED THERAPEUTICS INC

GTHP·OTC·Life Sciences·CIK 0000924515

The company is a medical technology company that develops innovative medical devices. Its primary focus is the sales and marketing of its LuViva® Advanced Cervical Scan, a non-invasive device for detecting cervical cancer. LuViva uses biophotonics technology to identify cervical cancers and precancers by scanning the cervix with light and analyzing the reflected and fluorescent light. This device is designed to be a less invasive, painless, and convenient alternative to conventional tests, providing rapid results at the point of care. The company targets two main applications for LuViva. First, it serves as a cancer screening tool in the developing world, where infrastructure for traditional screening methods is limited or absent. Second, in the developed world, it functions as a triage following traditional screening to address the high rate of unnecessary and costly follow-up tests caused by false positive results. Cervical cancer screening is a significant area of diagnostic medicine, with approximately 2.0 billion women aged 15 and older in the developing world potentially eligible for screening with LuViva. Traditional Pap smear tests, while primary in the developed world, are expensive and require infrastructure and skills often lacking in developing countries.

GUIDED THERAPEUTICS INC (OTC:GTHP) is a publicly traded company in the Life Sciences sector. Wiseek monitors GTHP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Guided Therapeutics Posts $0 Revenue, $1.01M Q1 Loss; Advances FDA PMA Filing for Key Device
  • GUIDED THERAPEUTICS Reports Widening Q1 Loss, Reiterates Going Concern Warning Amid Heavy Dilution
  • Director & 10% Owner Exercises Warrants for $200K, Converts Preferred Stock, Increasing Common Holdings
  • Guided Therapeutics' 2025 Revenue Jumps to $0.77M, Posts $(0.04) EPS Loss; FDA Submission Nears
  • Guided Therapeutics Reports Going Concern Doubt, Material Weaknesses, and Significant Dilution Amidst Capital Raises

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$767K
Net Income
-$3.2M
Diluted EPS
-$0.04
Op. Cash Flow
-$1.07M
Free Cash Flow
-$1.07M
Gross Profit
$571K
Operating Income
-$2.37M
Cash & Equivalents
$63K
Total Debt
$0
Debt / Equity
0.00×
Net Margin
-416.7%
Shares Outstanding
86.15M sh
Source: 10-K · filed 2026-03-30 · accession 0001477932-26-001723
Browse all tickers starting with G →
$0.2028
52-week range · as of 2026-05-15 $0.0644 – $0.54
Market cap
$19.57M
Volume
2.9K (0.2× avg)
3-mo avg 18.5K
Live data · 2026-06-14 05:16 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GTHP - Latest Insights

GTHP
May 15, 2026, 1:21 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.200
Real-time Price: $0.20275 info
Change: +$0.00275 (+1%) info
Market Cap: $19.573M info
GTHP
May 15, 2026, 1:17 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.200
Real-time Price: $0.20275 info
Change: +$0.00275 (+1%) info
Market Cap: $19.573M info
GTHP
May 05, 2026, 6:21 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $0.200
Real-time Price: $0.20275 info
Change: +$0.00275 (+1%) info
Market Cap: $19.573M info
GTHP
Mar 31, 2026, 6:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.2464
Real-time Price: $0.20275 info
Change: -$0.04365 (-18%) info
Market Cap: $19.573M info
GTHP
Mar 30, 2026, 7:14 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.2464
Real-time Price: $0.20275 info
Change: -$0.04365 (-18%) info
Market Cap: $19.573M info
GTHP
Mar 09, 2026, 7:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.288
Real-time Price: $0.20275 info
Change: -$0.08525 (-30%) info
Market Cap: $19.573M info